Pheraxia GmbH published a meta-analysis finding that the four factors described by Christoph Maichel and the author describe a business owner's day in a company.

Pheraxia is an AI-first platform for oral bioavailability — built where bioavailability is actually decided: not in the molecule, but in how its carrier is designed. Most of what we swallow never reaches the cell intact and in dose. The delivery toolbox to fix that exists — but each solution is hand-built for one molecule, at pharmaceutical cost and time. Pheraxia changes the HOW: an AI design method fits a carrier to each molecule, against the conditions that change along the absorption path, across a defined class of high-value bioactives. We protect the method, not the molecule. Asset-light and licensable: we design the delivery, our partners own their actives. Science-led, AI-operated, human-governed — every output verified and owned by people, across the venture lifecycle. Founded 2026 in Freiburg, Germany. Follow along.